About Us
Zuventus is an emerging player in the field of Acute Respiratory Distress Syndrome (ARDS) management. We are dedicated to revolutionize the way ARDS is understood and treated. Our mission is to improve patient outcomes by offering innovative treatment options that address and reduce the mortality in ARDS.
We are committed to advancing the boundaries of ARDS management through our approach towards rigorous research, clinical excellence and patient-centric perspective.
As an emerging player, we are driven by the urgency to transform ARDS from a high mortality to a very low mortality condition. Join us in our mission in making the path toward improved health and well-being for all suffering from ARDS.
Our mission is to redefine the landscape of Acute Respiratory Distress Syndrome (ARDS) management through breakthrough innovation and unwavering dedication to patient well being. We are driven to empower physicians with innovative treatment options. We are committed to improve the mortality in ARDS patients, bringing well being to the patients and their families.
Our vision is to establish ourselves as an emerging leader in ARDS management, recognized for our trasnsformative contributions to the field. We envision a world where ARDS is effectively managed, by bringing down the mortality rates in ARDS, significantly. Our ultimate goal is to create a future where ARDS is no longer a life-threatning condition, but a highly manageable challenge, that healthcare professionals are equipped to address with confidence and precision.
.png)
ARDS is an outcome of factors such as pneumonia, non-pulmonary sepsis, gastric aspiration, trauma, pancreatitis, burns, inhalation injury, drug overdose, multiple transfusions, or shock. World over, health practitioners face a lot of challenges while managing in ARDS including peaking mortality rates, High frequency oscillatory ventilation, Extracorporeal carbon dioxide removal etc. So there is a need for an affordable yet life-saving offering that reduces the uncertainty in patients who have been shifted on ventilators. Something we believe Aviptadil truly achieves.
For lives troubled with ARDS, we are creating a new ray of hope with Aviptadil. It is intravenous infusion by nature, which can be administered by infusion pump in escalating doses for 3 successive days to fight challenges such as reducing mortality rate and managing issues such as High frequency oscillatory ventilation, Extracorporeal carbon dioxide removal, etc..
Aviptadil has been engineered to have anti-inflammatory action, so it can block apoptosis and caspase-3 activation in the lung With the intent to bringing back as many lives as possible from the clutches of ventilator, we have even kept the pricing fairly economical.